Stock Information

• MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
  Mon, Sep 28, 2026 2:45 PM
• LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
  Mon, Sep 28, 2026 2:03 PM
• Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
  Mon, Sep 28, 2026 12:38 PM
• HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152
  Mon, Sep 28, 2026 6:28 AM
• Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases
  Mon, Sep 28, 2026 5:22 AM
• Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
  Fri, Sep 25, 2026 11:00 PM
• INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
  Fri, Sep 25, 2026 6:43 PM
• FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily
  Fri, Sep 25, 2026 2:53 PM
• Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data
  Thu, Sep 24, 2026 6:14 PM
• Incyte (INCY) Heads To EADV With New Skin Disease Trial Data
  Thu, Sep 24, 2026 1:15 AM

Financial data not available